WuXi TIDES, a unique Contract Research and Development Manufacturing Organization (CRDMO) platform, is an integral part of WuXi STA, a subsidiary of WuXi AppTec. WuXi TIDES offers our worldwide partners efficient, flexible, and high-quality solutions for the drug development of oligonucleotides, peptides and related synthetic conjugates (“TIDES” drugs). We greatly simplify the TIDES drug development by providing all discovery, CMC development and the entire manufacturing supply chain under one roof.
With over 1,000 scientists from 9 R&D and manufacturing sites, we offer discovery compound screening and synthesis, process development and manufacturing of novel monomers, linkers and ligands, oligonucleotides, peptides and complex synthetic conjugates at any scale. Beyond chemistry, we offer formulation development, manufacturing, labeling and distribution services in a variety of injectable dosage forms and filling formats including the Lipid Nanoparticle (LNP) drug delivery platform. Our comprehensive analytical method development, validation and testing platform will support your needs in TIDES drug development from discovery through clinical to commercial. Moreover, our Regulatory Affairs CMC team is experienced in preparing CMC dossiers to support global filings for TIDES new drug applications.
Why WuXi TIDES?
From discovery to development and commercialization all within WuXi STA with readily available large R&D and manufacturing capacity
API process R&D and manufacturing, formulation development and manufacturing, analytical, CMC dossier preparation and clinical supply services
Comprehensive Analytical Platform
Method development and validation, IPC and release testing, characterization, stability
Oligonucleotide: Biocatalysis for gRNA synthesis, Thin Film Evaporation (TFE)
Peptide: Reactor-in-series (with PAT data collection) , continues flow chromatography, Tangential Flow Filtration (TFF) / precipitation
Global Quality Standard
One quality system across all sites approved by major regulatory agencies in the world
Seamless collaboration among oligonucleotide, peptide and small molecule teams